NLRP3 and coronary artery disorder: Notably, drugs aimed at IL-1, IL-6, and NLRP3 are under active investigation.658–663 Colchicine, a microtubule inhibitor and non-selective NLRP3 inhibitor, has demonstrated significant efficacy in reducing the incidence of MACE in patients with coronary artery disease and myocardial infarction, as evidenced by the results of two large-scale clinical trials, Lodoco2 and COLCOT.47,690 Following these findings, the FDA approved colchicine as an anti-inflammatory treatment for cardiovascular disease, marking a significant advancement in targeted anti-inflammatory strategies.